drugset / Trial / NCT07353957

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

NCT07353957

Phase 2 Withdrawn Merus B.V.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The study will test the efficacy and safety of petosemtamab in combination with Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer.

Timeline

Start
2025-03-27
Primary completion
2028-05-31
Completion
2031-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody
Subject Petosemtamab Monoclonal antibody